Why BIVI was halted on Sep 15 2026: phase 2 trial results
BIVI+7.0%on Tue Sep 15 2026
BioVie, Inc. Common Stock was up 7.0% on the day at $1.92, ranked #178 on 1.0× its usual five-minute volume, when TapeRank recorded this trading halt at 07:25 ET during the pre-market session when it was halted.
WHAT THE ROW LOOKED LIKE
LAST1.92
DAY▲ 7.0%
5 MIN▲ 0.02%
5M RVOL1.0×
5M $VOL$6K
FLOAT*8.5M
RANK#178
SESSIONPRE-MARKET
* FLOAT IS SHARES OUTSTANDING; TRUE FREE FLOAT IS NOT AVAILABLE
AI VERDICT
JUSTIFIEDCONFIDENCE5/5
BIVI is up 14% pre-market after reporting positive Phase 2 Long COVID subgroup results and an advantage over placebo on 21 of 22 endpoints. The move is supported by a material clinical readout, although the overall population did not achieve statistical significance and the strongest results were limited to prespecified subgroups.
WHYA 14% pre-market gain is proportionate to a mixed but directionally positive Phase 2 readout, rather than obviously exceeding the news.
ANALYZED 08:01 ET · <1 MIN AGO · OPENAI/GPT-5.6-LUNA
FILINGS · 24H BEFORE THE MOVE
SESSION LEVELS AT CAPTURE
VWAP1.88
HOD1.98
LOD1.77
OR HIGH—
OR LOW—
PREV CLOSE1.79
PM HIGH1.98
PM LOW1.77
GAP▲ 7.04% (indicated)
— MEANS THE LEVEL DID NOT EXIST YET AT THAT INSTANT, NOT ZERO